KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials.

Alicia K Morgans, Sara Ekberg, Martin Boegemann, Noman Paracha, Elaine Gallagher, Alessandro Gasparini, Michael J Crowther, Neal Shore, Christopher J D Wallis

Eur Urol Oncol S2588-9311(26)00067-2

PMID41956912
PMCID-
DOI10.1016/j.euo.2026.03.009
发表日期2026-04-09
摘要

摘要

BACKGROUND: Maintaining quality of life (QoL) is an important treatment goal in metastatic hormone-sensitive prostate cancer (mHSPC). Evidence remains limited regarding longitudinal QoL changes, prognostic value, and contribution to treatment benefit. OBJECTIVE: We examined longitudinal QoL patterns, their association with castration resistance or death (CROD) and radiological progression or death (rPFS), and the contribution of QoL to the effect of darolutamide. DESIGN, SETTING AND PARTICIPANTS: We analyzed data from two randomized phase III trials: ARASENS (ADT + docetaxel ± darolutamide) and ARANOTE (ADT ± darolutamide). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: QoL was assessed using NCCN-FACT FPSI-17 (ARASENS) and FACT-P (ARANOTE). Joint models linked QoL with CROD (ARASENS) and rPFS (ARANOTE), accounting for informative missingness. RESULTS AND LIMITATIONS: Patients receiving darolutamide maintained higher QoL versus those receiving placebo. QoL decline meeting the minimally important difference (MID) was associated with higher CROD rate and shorter rPFS (HR 2.58 [95% CI: 1.76-3.78] and HR 1.32 [1.00-1.75], respectively). Higher baseline QoL was associated with improved rPFS for FACT-P (HR 0.84 [0.76-0.92] per MID) but no clear association was observed for NCCN-FACT FPSI-17 (HR 0.95 [0.89-1.02]). Joint modeling indicated that the total effect of darolutamide was largely driven by a direct component, with a smaller indirect component related to preserved QoL. Interpretation is limited by differences in disease progression definitions and QoL instruments between trials. CONCLUSIONS: Darolutamide improved CROD/rPFS while maintaining QoL better than placebo. QoL decline preceded progression, supporting routine QoL monitoring as an early marker of disease progression.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。